| Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses RH Thompson, T Atwell, G Schmit, CM Lohse, AN Kurup, A Weisbrod, ... European urology 67 (2), 252-259, 2015 | 443 | 2015 |
| Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice ZA Khan, E Boscolo, A Picard, S Psutka, JM Melero-Martin, TC Bartch, ... The Journal of clinical investigation 118 (7), 2592-2599, 2008 | 404 | 2008 |
| Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma SP Psutka, AS Feldman, WS McDougal, FJ McGovern, P Mueller, ... European urology 63 (3), 486-492, 2013 | 361 | 2013 |
| Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer‐specific and all‐cause mortality SP Psutka, A Carrasco, GD Schmit, MR Moynagh, SA Boorjian, I Frank, ... Cancer 120 (18), 2910-2918, 2014 | 299 | 2014 |
| Epidemiology of renal cell carcinoma: 2022 update L Bukavina, K Bensalah, F Bray, M Carlo, B Challacombe, JA Karam, ... European urology 82 (5), 529-542, 2022 | 255 | 2022 |
| Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines SB Stewart, RH Thompson, SP Psutka, JC Cheville, CM Lohse, ... Journal of Clinical Oncology 32 (36), 4059-4065, 2014 | 145 | 2014 |
| Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma SP Psutka, BC Leibovich Therapeutic advances in urology 7 (4), 216-229, 2015 | 143 | 2015 |
| Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer SP Psutka, SA Boorjian, MR Moynagh, GD Schmit, BA Costello, ... The Journal of urology 195 (2), 270-276, 2016 | 129 | 2016 |
| Epidemiology, screening, and prevention of bladder cancer N Lobo, L Afferi, M Moschini, H Mostafid, S Porten, SP Psutka, S Gupta, ... European urology oncology 5 (6), 628-639, 2022 | 112 | 2022 |
| Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus SP Psutka, SA Boorjian, RH Thompson, GD Schmit, JJ Schmitz, TC Bower, ... BJU international 116 (3), 388-396, 2015 | 94 | 2015 |
| Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach SB Stewart-Merrill, RH Thompson, SA Boorjian, SP Psutka, CM Lohse, ... Journal of Clinical Oncology 33 (35), 4151-4157, 2015 | 85 | 2015 |
| Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting SP Psutka, SA Boorjian, MR Moynagh, GD Schmit, I Frank, A Carrasco, ... The Journal of urology 193 (5), 1507-1513, 2015 | 84 | 2015 |
| Urethral foreign bodies: clinical presentation and management CJ Palmer, M Houlihan, SP Psutka, KA Ellis, P Vidal, CMP Hollowell Urology 97, 257-260, 2016 | 73 | 2016 |
| Standardizing the definition of biochemical recurrence after radical prostatectomy—what prostate specific antigen cut point best predicts a durable increase and subsequent … A Toussi, SB Stewart-Merrill, SA Boorjian, SP Psutka, RH Thompson, ... The Journal of urology 195 (6), 1754-1759, 2016 | 73 | 2016 |
| Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline JA Coleman, PE Clark, BR Bixler, DI Buckley, SS Chang, R Chou, ... Journal of Urology 209 (6), 1071-1081, 2023 | 65 | 2023 |
| Staging the host: personalizing risk assessment for radical cystectomy patients SP Psutka, DA Barocas, JWF Catto, JL Gore, CT Lee, TM Morgan, ... European Urology Oncology 1 (4), 292-304, 2018 | 64 | 2018 |
| Validation study of a new semi-automated software program for CT body composition analysis N Takahashi, M Sugimoto, SP Psutka, B Chen, MR Moynagh, RE Carter Abdominal radiology 42, 2369-2375, 2017 | 59 | 2017 |
| Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I. A Feifer, JM Taylor, M Shouery, GD Steinberg, WM Stadler, ... Journal of Clinical Oncology 29 (7_suppl), 240-240, 2011 | 56 | 2011 |
| Uncertainty and perception of danger among patients undergoing treatment for prostate cancer MW Kazer, DE Bailey Jr, J Chipman, SP Psutka, J Hardy, L Hembroff, ... BJU international 111 (3b), E84-E91, 2013 | 55 | 2013 |
| Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis Z Wu, Q Chen, L Qu, M Li, L Wang, MC Mir, U Carbonara, SD Pandolfo, ... European urology 81 (4), 414-425, 2022 | 52 | 2022 |
